| European Medicines Agency - Eligible Group Status - COMP [Committee for Orphan Medicinal Products] - SAWP [Scientific Advice Working Party]. | 呼吸系統
> 肺纖維化 | 監管合作關係
> 與監管機構合作 | Not specified | International | Rarely | 119039359117 |
| When new drugs are approved by the EU medicines agency, we work to represent patient interest with the health service and government agency responsible for approving the drug in Ireland and regulating pricing of new drugs. | 呼吸系統
> 間質性肺疾病（ILD） | 監管合作關係
> 與監管機構合作 | 5,000 | National | Sometimes | 119044171823 |
| Submission on Lutathera for reimbursement decision. | 巨蟹座
> 癌症：神經內分泌腫瘤（NET） | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | 1,000 | National | Rarely | 119039308095 |
| We share the patient experience of living with a condition as part of the reimbursement process. | 神經肌肉
> 神經肌肉疾病：大多數類型 | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | 1,000 | National | Sometimes | 119047368493 |
| We submitted our support to the NCPE [National Centre for Pharmacoeconomics] for their appraisal of Lutathera [used to treat adults with certain unresectable or metastatic gastroenteropancreatic neuroendocrine tumors]. | 巨蟹座
> 癌症：神經內分泌腫瘤（NET） | 監管合作關係
> 參與健康技術評估（HTA）及給付審查 | 100 | National | Rarely | 119051190597 |
| Drugs for ataxia are very rare, so we only make submissions as they become available. | 神經退化性
> 共濟失調 | 監管合作關係
> 貢獻至行銷授權申請 | 1,000 | National | Rarely | 119020208311 |
| European Medicines Agency - Eligible Group Status - COMP [Committee for Orphan Medicinal Products] - SAWP [Scientific Advice Working Party]. | 呼吸系統
> 肺纖維化 | 監管合作關係
> 出席/主持與政策制定者/監管機構的會議 | Not specified | International | Rarely | 119039359117 |
| Meetings with Government Representatives and Department of Health regarding the availability of certain DMTs [Disease-Modifying Therapies primarily used for multiple sclerosis and various autoimmune conditions (like rheumatoid arthritis)]. | 神經系統
> 多發性硬化症 | 監管合作關係
> 出席/主持與政策制定者/監管機構的會議 | 10,000 | National | Regularly | 119074666617 |
| National organization is affiliated with European groups which attempt to have influence. | 一般健康
> 健康素養 | 監管合作關係
> 與其他醫療倡導者 | 100 | National | Rarely | 119052876993 |
| Advocacy/public affairs messaging about improving reimbursement decision-making for drugs in Ireland. | 巨蟹座
> 癌症：大多數類型 | 影響政策與立法
> 影響醫療保健政策與法規 | 10,000 | National | Rarely | 119063937918 |
| We have advocated for our members to our government representatives at yearly events where we have been invited to government buildings to present to an invited group. | 病患倡導
> 健康倡議者 | 影響政策與立法
> 參與公開聽證會及諮詢 | 5,000 | National | Rarely | 119047297038 |
| We have advocated for our members to our government representatives at yearly events where we have been invited to government buildings to present to an invited group. | 病患倡導
> 健康倡議者 | 影響政策與立法
> 動員國會議員與政治領袖 | 5,000 | National | Rarely | 119047297038 |
| We advocate for the most efficient medicine to be available and reimbursed for heart failure patients. | 心臟
> 心臟衰竭 | 影響政策與立法
> 解決醫療照護中的障礙/異常問題 | 5,000 | National | Sometimes | 119051411038 |
| When new drugs are approved by the EU medicines agency, we work to represent patient interest with the health service and government agency responsible for approving the drug in Ireland and regulating pricing of new drugs. | 呼吸系統
> 間質性肺疾病（ILD） | 定價與可負擔性倡議
> 參與價格審查委員會談判 | 5,000 | National | Sometimes | 119044171823 |
| Advocacy/public affairs messaging about improving reimbursement decision-making for drugs in Ireland. | 巨蟹座
> 癌症：大多數類型 | 定價與可負擔性倡議
> 倡導將產品納入給付清單/國家藥品目錄 | 10,000 | National | Rarely | 119063937918 |
| Equity of access: Public patients can wait a lot longer for access to meds approved by EMA [European Medicines Agency], versus private patients whose insurance companies reimburse. | 病患倡導
> 健康倡議者 | 改善存取路徑
> 促進藥品/醫療保健的公平取得 | 1,000 | National | Sometimes | 119044976833 |
| We advocate for the most efficient medicine to be available and reimbursed for heart failure patients. | 心臟
> 心臟衰竭 | 改善存取路徑
> 促進藥品/醫療保健的公平取得 | 5,000 | National | Sometimes | 119051411038 |
| Meetings with Government Representatives and Department of Health regarding the availability of certain DMTs [Disease-Modifying Therapies primarily used for multiple sclerosis and various autoimmune conditions (like rheumatoid arthritis)]. | 神經系統
> 多發性硬化症 | 改善存取路徑
> 促進藥品/醫療保健的公平取得 | 10,000 | National | Regularly | 119074666617 |
| Equity of access: Public patients can wait a lot longer for access to meds approved by EMA [European Medicines Agency], versus private patients whose insurance companies reimburse. | 病患倡導
> 健康倡議者 | 改善存取路徑
> 解決存取與管理方面的差異 | 1,000 | National | Sometimes | 119044976833 |
| Drugs for ataxia are very rare, so we only make submissions as they become available. | 神經退化性
> 共濟失調 | 改善存取路徑
> 改善罕見/極罕見療法的取得管道 | 1,000 | National | Rarely | 119020208311 |
| During the course of projects based on issues experienced by the community. | 腸胃道
> IBD | 以實證為基礎的病患意見
> 運用病患故事與親身經歷敘述 | 5,000 | National | Sometimes | 119020296590 |
| We share the patient experience of living with a condition as part of the reimbursement process. | 神經肌肉
> 神經肌肉疾病：大多數類型 | 以實證為基礎的病患意見
> 運用病患故事與親身經歷敘述 | 1,000 | National | Sometimes | 119047368493 |
互動
行動與倡議
9 提及
